A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A
Yıl: 2020 Cilt: 21 Sayı: 3 Sayfa Aralığı: 177 - 181 Metin Dili: İngilizce DOI: 10.4274/imj.galenos.2020.93753 İndeks Tarihi: 26-10-2020
A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A
Öz: Introduction: Vestibular migraine is a clinical entitycharacterised by dizziness. Additionally, it has no proventreatment options, and the goal is to control vestibularsymptoms by reducing migraine attacks. This study aimed toinvestigate the effect of onabotulinum toxin type A in reducingvestibular migraine symptoms.Methods: Between 2014 and 2019, the charts of 80 patientswith migraine who received onabotulinum toxin type Atreatment were collected. Among them, 22 patients who metthe criteria of vestibular migraine were included in the study.The treatment outcomes of these patients were investigated.Migraine Disability Assessment scale (MIDAS), Visual Analoguescale (VAS) and Dizziness Handicap index (DHI) were used forevaluation. Pre-treatment and post-treatment values werecompared.Results: The mean age of the patients was 41.5 years. WhenMIDAS, DHI and VAS scores were compared, the post-treatmentscores were found to be statistically significantly lower than thepre-treatment scores (p<0.05).Conclusion: Botulinum toxin treatment may be promising inpatients with vestibular migraine. The limitation of this studyis our relatively small group of patients. Therefore, there is aneed for prospective work with a larger group of patients.
Anahtar Kelime: Vestibüler Migren için Yeni Bir Tedavi Seçeneği: Onabotulinum Toksin Tip-A
Öz: Amaç: Vestibüler migren, migren hastalarında baş dönmesi ile karakterize klinik bir durumdur. Ek olarak, kanıtlanmış bir tedavi seçeneği bulunmamakta olup, hedef, migren ataklarını azaltarak vestibuler semptomları kontrol altına almaktır. Bu çalışmanın amacı Onabotulinum toksin tip A’nın vestibüler migren hastalarının semptomlarını azaltmadaki etkisini araştırmaktır. Yöntemler: 2014-2019 yılları arasında migren tanısıyla onabotulinum toksin tip A tedavisi alan olan 80 hastanın verileri retrospektif olarak toplandı. Çalışmaya, vestibüler migren kriterlerini karşılayan 22 hasta dahil edildi. Bu hastaların tedavi sonuçları araştırıldı. Migren Engellilik Değerlendirme ölçeği (MIDAS), Görsel Analog ölçeği (VAS) ve Dizziness Handikap indeksi (DHI) değerlendirildi. Tedavi öncesi ve tedavi sonrası değerler karşılaştırıldı. Bulgular: Hastaların yaş ortalaması 41,5 olarak bulundu. MIDAS, DHI ve VAS skorları karşılaştırıldığında, tedavi sonrası skorların tedavi öncesi skorlardan istatistiksel olarak anlamlı derecede düşük olduğu saptandı. (p<0,05). Sonuç: Vestibüler migren hastalarında botulinum toksin tedavisi umut verici olabilir. Bu çalışmanın kısıtlılığı nispeten küçük hasta grubumuzdur. Bu nedenle, daha büyük hasta grubuyla ileriye dönük bir çalışmaya ihtiyaç vardır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Bolay H, Bayazit YA, Gündüz B, Ugur AK, Akçali D, Altunyay S, et al. Subclinical dysfunction of cochlea and cochlear effer-ents in migraine: an otoacoustic emission study. Cephalalgia 2008; 28: 309-17.
- 2. Dash AK, Panda N, Khandelwal G, Lal V, Mann SS. Migraineand audiovestibular dysfunction: is there a correlation. Am J Otolaryngol 2008; 29: 295-9.
- 3. Cal R, Bahmad F Jr. Migraine associated with auditory-vestibular dysfunction. Braz J Otorhinolaryngol 2008; 74: 606-12.
- 4. Liveing E. On megrim, sick-headache, and some allied disorders. London, UK: Churchill; 1873.
- 5. Kayan A, Hood JD. Neuro-otological manifestations of migraine. Brain 1984; 107: 1123-42.
- 6. Dieterich M, Brandt T. Episodic vertigo related to migraine (90cases): vestibular migraine. J Neurol 1999; 246: 883-92.
- 7. Akdal G. Clinical Features of Migrainous Vertigo. J Neurol Sci Turk 2008; 15: 92-5.
- 8. Neuhauser H, Lempert T. Vertigo and dizziness related to migraine: diagnostic challenge. Cephalalgia 2004; 24: 83-91.
- 9. Kutay Ö, Akdal G, Keskinoğlu P, Balcı BD, Alkın T. Vestibular migraine patients are more anxious than migraine patients without vestibular symptoms. J Neurol 2017; 264(Suppl 1): 37-41.
- 10. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013; 33: 629-808.
- 11. Lempert T, Neuhauser H, Daroff RB. Vertigo as a symptom of migraine. Ann N Y Acad Sci 2009; 1164: 242-51.
- 12. Fotuhi M, Glaun B, Quan SY, Sofare T. Vestibular migraine: a critical review of treatment trials. J Neurol 2009; 256: 711-16.
- 13. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000; 40: 445-50.
- 14. Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C, et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebocontrolled trial. Headache 2005; 45: 293-307.
- 15. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC, et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebocontrolled trial. Mayo Clin Proc 2005; 80: 1126-37.
- 16. Silberstein SD, Göbel H, Jensen R, Elkind AH, Degryse R, Walcott JMCM, et. al. Botulinum toxin type A in the prophylactic treatment of chronic tensiontype headache: a multicenter, double-blind, randomized, placebocontroled, parallel-group study. Cephalalgia 2006; 26: 790-800.
- 17. Aurora SK, Dodick DW, Turkel CC, DeGreyse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793-803.
- 18. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGreyse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 804-14.
- 19. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, et al. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci 2013; 331: 48-56.
- 20. Whitcup SM, Turkel CC, DeGryse RE, Brin MF. Development of onabotulinumtoxinA for chronic migraine. Ann N Y Acad Sci 2014; 1329: 67- 80.
- 21. Maione A. Migraine-related vertigo: diagnostic criteria and prophylactic treatment. Laryngoscope 2006; 116: 1782-86.
- 22. Reploeg MD, Goebel JA. Migraine-associated dizziness: patientcharacteristics and management options. Otol Neurotol 2002; 23: 364-71.
- 23. Salmito MC, Duarte JA, Morganti LO, Brandão PV, Nakao BH, Villa TR, et. al. Prophylactic treatment of vestibular migraine. Braz J Otorhinolaryngol 2017; 83: 404-10.
- 24. Johnson GD. Medical management of migraine-related dizziness and vertigo. Laryngoscope 1998; 108: 1-28.
- 25. Baier B, Winkenwerder E, Dieterich M. “Vestibular migraine”: Effects of prophylactic therapy with various drugs. A retrospective study. J Neurol 2009; 256: 436-42.
- 26. Celiker A, Bir LS, Ardiç N. Effects of valproate on vestibular symptoms and electronystagmographic findings in migraine patients. Clin Neuropharmacol 2007; 30: 213-21.
- 27. Carmona S, Settecase N. Use of topiramate (Topamax) in a subgroup of migraine-vertigo patients with auditory symptoms. Ann N Y Acad Sci 2005; 1039: 517-20.
- 28. Bisdorff AR. Treatment of migraine related vertigo with lamotrigine an observational study. Bull Soc Sci Med Luxembourg 2004; 2: 103-8.
- 29. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003; 43: 16-24.
- 30. Aoki KR. Pharmacology and immunology of botulinum neurotoxins. Int Ophtalmol Clin 2005; 45: 25-37.
- 31. Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L. Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain 2009; 141: 60-9.
- 32. Cernuda-Morollon E, Ramon C, Larrosa D, Alvarez R, Riesco N, Pascual J. Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?. Cephalalgia 2015; 35: 864-8.
| APA | SURMELI R, ERDEN HABESOGLU T (2020). A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A. , 177 - 181. 10.4274/imj.galenos.2020.93753 |
| Chicago | SURMELI Reyhan,ERDEN HABESOGLU Tulay A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A. (2020): 177 - 181. 10.4274/imj.galenos.2020.93753 |
| MLA | SURMELI Reyhan,ERDEN HABESOGLU Tulay A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A. , 2020, ss.177 - 181. 10.4274/imj.galenos.2020.93753 |
| AMA | SURMELI R,ERDEN HABESOGLU T A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A. . 2020; 177 - 181. 10.4274/imj.galenos.2020.93753 |
| Vancouver | SURMELI R,ERDEN HABESOGLU T A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A. . 2020; 177 - 181. 10.4274/imj.galenos.2020.93753 |
| IEEE | SURMELI R,ERDEN HABESOGLU T "A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A." , ss.177 - 181, 2020. 10.4274/imj.galenos.2020.93753 |
| ISNAD | SURMELI, Reyhan - ERDEN HABESOGLU, Tulay. "A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A". (2020), 177-181. https://doi.org/10.4274/imj.galenos.2020.93753 |
| APA | SURMELI R, ERDEN HABESOGLU T (2020). A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A. İstanbul Medical Journal, 21(3), 177 - 181. 10.4274/imj.galenos.2020.93753 |
| Chicago | SURMELI Reyhan,ERDEN HABESOGLU Tulay A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A. İstanbul Medical Journal 21, no.3 (2020): 177 - 181. 10.4274/imj.galenos.2020.93753 |
| MLA | SURMELI Reyhan,ERDEN HABESOGLU Tulay A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A. İstanbul Medical Journal, vol.21, no.3, 2020, ss.177 - 181. 10.4274/imj.galenos.2020.93753 |
| AMA | SURMELI R,ERDEN HABESOGLU T A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A. İstanbul Medical Journal. 2020; 21(3): 177 - 181. 10.4274/imj.galenos.2020.93753 |
| Vancouver | SURMELI R,ERDEN HABESOGLU T A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A. İstanbul Medical Journal. 2020; 21(3): 177 - 181. 10.4274/imj.galenos.2020.93753 |
| IEEE | SURMELI R,ERDEN HABESOGLU T "A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A." İstanbul Medical Journal, 21, ss.177 - 181, 2020. 10.4274/imj.galenos.2020.93753 |
| ISNAD | SURMELI, Reyhan - ERDEN HABESOGLU, Tulay. "A New Treatment Option for Vestibular Migraine: Onabotulinum Toxin Type A". İstanbul Medical Journal 21/3 (2020), 177-181. https://doi.org/10.4274/imj.galenos.2020.93753 |
